Page 54 of 88
12 to apply training and cultivation of drug management continually.
5.6. Indonesian Indigenous Drug Development and Cultivation Program
The aim of this program is to develop and increase Indonesian indigenous drugs which have high quality and safety as well as have real efficacy that is strictly tested, and which
have been used widely for self treatment by the society or used in the formal health services.
The target of this program is Indonesian indigenous drugs OAI to be developed and utilized widely primarily in the formal health services and for export.
The principle activities included in this program are: 1
standardization of simplicia including the extracts of OAI; 2
development of agri-medicine and cross-sectoral cooperation; 3
leading the use of OAI phytopharmaceuticals in hospitals and puskesmas; 4
mapping OAI and ethno-pharmacognoxy; 5
construction of OAI information center; 6
increasing export of OAI; and 7
development of cooperation network between OAI industries and research institution in environment.
5.7. Pharmaceutical Industries Cultivation and Development Program
The aim of this program is to strengthen the structure and competitiveness of Indonesian pharmaceutical industries so as to be able to fulfill domestic drug needs and for export at
reasonable price and with international standard of quality. The target of this program is to increase autonomy of the national pharmaceutical
industries including those producing medicinal raw materials that are economic and efficient by using domestic resources.
The main activities included are among others the following: 1
to restructure pharmaceutical industries by strengthening the interrelation and synergy between the up-stream and down-stream industries;
2 to develop business climate that is conducive with healthy competition;
3 to offer various facilitation and incentives in order to increase export;
4 strategic alliance of national pharmaceutical industries with multi national industries
to expand export; and 5
to increase efficiency and competitiveness of pharmaceutical industries through dynamic deregulation.
6. Program Principle of Health Policy and Management Development
